诺华(NVS.US)siRNA疗法Leqvio再获FDA批准用于降低LDL-C

智通财经
Aug 01
【诺华(NVS.US)siRNA疗法Leqvio再获FDA批准用于降低LDL-C】智通财经APP获悉,江苏诺华(Novartis)(NVS.US)公司今日宣布,美国FDA已批准其每年两次给药的小干扰RNA(siRNA)疗法Leqvio(inclisiran)的扩展适应症申请,允许其作为单药,与饮食控制和运动联合使用,以降低成人高胆固醇血症患者的低密度脂蛋白胆固醇(LDL-C)水平。根据新闻稿,美国FDA根据该PCSK9靶向疗法降低LDL-C的积极数据,主动要求更新该药品的标签。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10